Search

Displaying results 5951 - 5960 of 7479 in total
  1. Drug

    3-hydroxyanthranilic acid

    go.drugbank.com/drugs/DB03644
    Experimental

    An oxidation product of tryptophan metabolism. It may be a free radical scavenger and a carcinogen.

  2. Drug

    Methylthioinosine

    go.drugbank.com/drugs/DB02896
    Experimental

    An analog of inosine with a methylthio group replacing the hydroxyl group in the 6-position.

  3. Drug

    Zeatin

    go.drugbank.com/drugs/DB11337
    Investigational

    An aminopurine factor in plant extracts that induces cell division. (Grant & Hackh's Chemical Dict, 5th ed)

  4. Drug

    LB-P8

    go.drugbank.com/drugs/DB18535
    Investigational

    LB-P8 is an investigational live biotherapeutic product consisting of a single bacterial strain (_Leuconostoc citreum_).

  5. Drug

    MCMV5322A

    go.drugbank.com/drugs/DB17763
    Investigational

    MCMV5322A is an anticytomegalovirus monoclonal IgG1 antibody used in combination with [MCMV3068A] to form RG7667.[A259362]

  6. Drug

    MCMV3068A

    go.drugbank.com/drugs/DB17764
    Investigational

    MCMV3068A is an anticytomegalovirus monoclonal IgG1 antibody used in combination with [MCMV5322A] to form RG7667.[A259362]

  7. Drug

    AN-9

    go.drugbank.com/drugs/DB05103
    Investigational

    Pivaloyloxymethyl butyrate (AN-9), an acyloxyalkyl ester prodrug of butyric acid (BA), exhibited low toxicity and significant anticancer activity in vitro and in vivo.

    Synonyms: AN-9
  8. Drug

    Brifentanil

    go.drugbank.com/drugs/DB09172
    ExperimentalIllicit

    Brifentanil (also known as A-3331) is an analog of fentanyl, a potent opioid. This drug is classified as an opioid analgesic and was developed in the early 1990s.

  9. Drug

    Pascolizumab

    go.drugbank.com/drugs/DB06560
    Investigational

    Pascolizumab (SB 240683) is a humanized anti-interleukin-4 antibody with therapeutic potential in asthma.

  10. Drug

    Cannabinor

    go.drugbank.com/drugs/DB05048
    Experimental

    Cannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.